Identification With the Aggressor (IWA)
Launched by TEL AVIV UNIVERSITY · Jan 14, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Background: Abuse is a severe trauma that has multiple psychological implications. One of the most paradoxical effects of CA is the identification with the aggressor (IWA) phenomenon. Research to date has indicated associations between IWA and various negative outcomes, such as PTSD, dissociation, guilt, suicidality, and increased likelihood of returning to abusive relationships . Nonetheless, these studies were based on a cross-sectional design, and thus excluded the possibility of establishing causality or shedding light on the complex dynamics of IWA. In addition, to the best of our know...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Good command of Hebrew language
- • Age 18 or older
- Exclusion Criteria:
- • Diagnosis of dissociative identity disorder
- • Persistent drug use
- • Diagnosis of autism spectrum disorder.
- • Hearing or vision difficulties (that may impair the experimental manipulation and participants' ability to complete the Reading the Mind in the Eyes and the IAT tasks).
- • Being currently subjected to abuse
- • Suicidal risk, as assessed by a clinical interview.
About Tel Aviv University
Tel Aviv University (TAU) is a leading research institution in Israel, renowned for its commitment to advancing knowledge and innovation across various fields, including medicine and biomedical research. With a strong emphasis on interdisciplinary collaboration, TAU conducts cutting-edge clinical trials aimed at improving healthcare outcomes and developing novel therapeutic strategies. The university's robust network of researchers, state-of-the-art facilities, and partnerships with healthcare organizations enable it to contribute significantly to the global medical research community, fostering advancements that address critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Yael Lahav, Phd
Principal Investigator
Tel Aviv University
Danny Horesh, Phd
Principal Investigator
Bar Ilan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported